Status: Recruiting
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Participants needed: 1,800
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Altimmune, Inc.Updated: Sep 23, 2026Locations: 9
Eligibility criteria
No significant changes in body weight (±5%) and not participating in a structure... [+3]
Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic... [+1]